Patent · US Active

Antibody-drug conjugate

US11633493B2 · kind B2 · utility

0Cited by

19References

14Claims

0Family size

Assignee

DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

Takeshi Masuda · Tokyo, JP
Hiroyuki Naito · Tokyo, JP
Takashi Nakada · Tokyo, JP
Masao Yoshida · Tokyo, JP
Shinji Ashida · Tokyo, JP
Hideki Miyazaki · Tokyo, JP
Yuji Kasuya · Tokyo, JP
Koji Morita · Tokyo, JP
Yuki Abe · Tokyo, JP
Yusuke Ogitani · Tokyo, JP

Key dates

Filing date	Mar 24, 2020
Grant date	Apr 25, 2023
Priority date	—
Expiry date	Apr 10, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.